DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Phase 1

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2022-09-15

Last Posted Date: 2022-09-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 40

Registration Number: NCT05541445

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer

Not Applicable

Completed

Conditions: Esophageal Cancer

Interventions: Device: cushion

First Posted Date: 2022-09-15

Last Posted Date: 2024-06-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 134

Registration Number: NCT05542680

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma

Completed

Conditions: Gastric Cancer

Interventions: Drug: SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody

First Posted Date: 2022-09-14

Last Posted Date: 2024-04-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 70

Registration Number: NCT05540145

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, China

Mechanical Bowel Preparation Versus no Bowel Preparation for Esophageal Cancer Surgery

Not Applicable

Completed

Conditions: Esophageal Cancer

Interventions: Procedure: No MBP

First Posted Date: 2022-09-01

Last Posted Date: 2024-05-07

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 652

Registration Number: NCT05523960

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib
Drug: HAIC

First Posted Date: 2022-08-22

Last Posted Date: 2022-08-22

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT05511051

Locations: 🇨🇳
People's Hospital of Inner Mongolia, Hohhot, China
🇨🇳
Dalian Medial University Affiliated Second Hospital, Dalian, China
🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

Phase 2

Recruiting

Conditions: Patient-controlled Analgesia
NSAIDs
Opioid
Esophageal Cancer
Perioperative Analgesia

Interventions: Device: Patient-controlled analgesia pump
Drug: Preemptive flurbiprofen axetil
Drug: Postoperative flurbiprofen axetil

First Posted Date: 2022-08-17

Last Posted Date: 2025-03-20

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT05504265

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Intraperitoneal chemotherapy
Drug: Adjuvant systemic chemotherapy

First Posted Date: 2022-08-11

Last Posted Date: 2022-08-11

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 68

Registration Number: NCT05497739

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing, Beijing, China

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Tislelizumab

First Posted Date: 2022-07-08

Last Posted Date: 2022-07-08

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 50

Registration Number: NCT05448885

Locations: 🇨🇳
National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC, Beijing, Beijing, China

Multi-center Study of Deep Learning AI in Breast Mass

Conditions: Breast Neoplasms

First Posted Date: 2022-07-05

Last Posted Date: 2022-07-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 1122

Registration Number: NCT05443672

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

Phase 2

Recruiting

Conditions: Limited Stage Small Cell Lung Cancer

Interventions: Drug: HLX10
Radiation: hypofractionated radiotherapy
Radiation: Prophylactic Cranial Irradiation (PCI)

First Posted Date: 2022-07-05

Last Posted Date: 2024-05-07

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 55

Registration Number: NCT05443646

Locations: 🇨🇳
Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China
🇨🇳
Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy